-
-
-
-
-
-
-
ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
-
-
-
-
-
-
-
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
1,222,855 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

